Non-invasive models for predicting histology in patients with chronic hepatitis B

Liver International

Volumn 26, Issue 6, 2006, Pages 666-672

  Wai, Chun Tao ^a   Cheng, Chee Leong ^b   Wee, Aileen ^b   Dan, Yock Young ^a   Chan, Edwin ^c   Chua, Winnie ^a   Mak, Belinda ^a   Oo, Aung Myat ^a   Lim, Seng Gee ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c MINISTRY OF HEALTH   (Singapore)

Author keywords

Bridging fibrosis; Diagnostic model; Hepatitis B virus; Liver biopsy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOLOGICAL MODEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INVASIVE MEASUREMENT; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; UNIVARIATE ANALYSIS; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PLATELET COUNT; RETROSPECTIVE STUDIES;

EID: 33745625066     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01287.x     Document Type: Article

References (36)

1. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. Gut 1999; 45 (Suppl. 4): IV1-11.
2. The EASL Jury. EASL International consensus conference on hepatitis B. J Hepatol 2003; 38: 533-40.
3. Lok A, MaMahon B J. Chronic hepatitis B. Hepatology 2001; 34: 1225-41.
4. Liaw Y F, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
5. Dienstag J L, Goldin R D, Heathcote E J, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
6. Liaw Y F, Sung J J, Chow W C, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
7. Douds A C, Joseph A E, Finlayson C, Maxwell J D. Is day case liver biopsy underutilised? Gut 1995; 37: 574-5.
8. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-73.
9. Fontana R J, Lok A S. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S57-64.
10. Bonacini M, Hadi G, Govindarajan S, Lindsay K L. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1302-4.
11. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-6.
12. Poynard T, Bedossa P, METAVIR and CLINIVIR cooperative study groups. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepatitis 1997; 4: 199-208.
13. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Importance of age in chronic hepatitis C virus infection. J Viral Hepatitis 1997; 4: 255-64.
14. Sheth S G, Flamm S L, Gordon F D, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8.
15. Reedy D W, Loo A T, Levine R A. AST/ALT ratio >or =1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Digest Dis Sci 1998; 43: 2156-9.
16. Forns X, Ampurdanes S, Llovet J M, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
17. Wai C T, Greenson J K, Fontana R J, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
18. Myers R P, Tainturier M H, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222-30.
19. Hui A Y, Chan H L, Wong V W, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100: 616-23.
20. Zeng M D, Lu L G, Mao Y M, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-45.
21. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
22. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-80.
23. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study. Gut 2006; 55: 403-8.
24. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: Evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985; 5: 367-75.
25. Okuda M, Li K, Beard M R, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
26. Nalpas B, Vassault A, Le Guillou A, et al. Serum activity of mitochondrial aspartate aminotransferase: A sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatology 1984; 4: 893-6.
27. Chu C M, Karayiannis P, Fowler M J, Monjardino J, Liaw Y F, Thomas H C. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985; 5: 431-4.
28. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBVDNA and anti-HBe. Gastroenterology 1986; 90: 1268-73.
29. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.
30. Aster R. Pooling of platelets in the spleen: Role in the pathogenesis of "hypersplenic"thrombocytopenia. J Clin Invest 1996;45: 645-57.
31. Kawasaki T, Takeshita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94: 1918-22.
32. Adinolfi L E, Giordano M G, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113: 590-5.
33. Sutedja D S, Wai C T, Teoh K F, et al. Persistent thrombocytopenia in liver transplant patients. Transplant Proc 2004; 36: 2331-3.
34. Al-Mohri H, Cooper C, Murphy T, Klein M B. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005; 6: 375-8.
35. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82.
36. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.